SuperworthLabcorp Holdings Inc. LH
Medical - Diagnostics & Research, Healthcare
$311.97
+0.08%
- Market cap
- $25.3B
- PE
- 25.8×
- 10y median 21.9×
- Forward PE
- Price to sales
- 1.8×
- EV/EBIT
- 20.7×
- Revenue, 12 months
- $14.3B
- +6% on a year ago
- Net margin
- 7.0%
- Free cash flow yield
- 4.6%
Labcorp trades at 25.8× trailing earnings, pricier than 70% of the last ten years. Revenue was $14.3B over the last twelve months, up 6% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $3B | $3.2B | $3.2B | $3.3B | $3.3B+10% | $3.3B+5% | $3.5B+10% | $3.6B+9% | $3.5B+6% | $3.5B+6% | $3.7B+6% | |
| Cost of revenue | $2.2B | $2.3B | $2.3B | $2.4B | $2.4B+10% | $2.4B+5% | $2.5B+8% | $2.5B+7% | $2.5B+4% | $2.5B+5% | $2.6B+6% |
| Gross profit | $821.4M | $897.3M | $926.4M | $904.4M | $896.3M+9% | $948M+6% | $1B+13% | $1B+13% | $993.2M+11% | $1B+7% | $1.1B+6% |
| R&D | $2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A | $532.9M | $508.4M | $557.8M | $568.6M | $595.2M+12% | $546M+7% | $579.3M+4% | $552.4M−3% | $538.6M−10% | $551M+1% | $577.2M−0% |
| −$122.8M | $321.3M | $294.8M | $254.1M | $216.5M | $326M+2% | $394.5M+34% | $396.6M+56% | $267.6M+24% | $380.8M+17% | $451.6M+15% | |
| Interest expense | $48.8M | $46.9M | $47.6M | $50.4M | $63.4M+30% | $56M+19% | $57.1M+20% | $56M+11% | $55M−13% | $55.1M−2% | $61.1M+7% |
| Pre-tax income | −$147.1M | $297.4M | $267.7M | $210.6M | $183.8M | $275.2M−8% | $304.7M+14% | $337M+60% | $190.6M+4% | $319.7M+16% | $386.4M+27% |
| $19.7M | $69.1M | $62.1M | $41M | $40.2M+104% | $62.2M−10% | $66.4M+7% | $75.5M+84% | $25.7M−36% | $41.7M−33% | $87.3M+32% | |
| Net income | −$167.1M | $228M | $205.3M | $169.3M | $143.4M | $212.8M−7% | $237.9M+16% | $261.1M+54% | $164.7M+15% | $277.8M+31% | $298.7M+26% |
| −$1.97 | $2.69 | $2.43 | $2.00 | $1.70 | $2.52−6% | $2.84+17% | $3.12+56% | $1.98+17% | $3.35+33% | $3.64+28% | |
| 84.9M | 84.7M | 84.3M | 84.4M | 84.2M−1% | 84.3M−1% | 83.9M−1% | 83.7M−1% | 83.2M−1% | 82.9M−2% | 82M−2% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Labcorp's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $42.5B | 35.6× | 35.0× | 6.5× | +8% | 15.9% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .